John Valliant, Chief Executive Officer at Fusion Pharmaceuticals Inc. (FUSN), sold 3,800 shares at $7.75 ($29K) on 2022-04-01, disclosed to the SEC on 2022-04-05.
Scheduled sale ($29k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.75 | 1,000 | $8K | 26.4% |
| 2 | $7.81 | 700 | $5K | 18.6% |
| 3 | $7.67 | 2,100 | $16K | 54.9% |
| Total | $7.72 avg | 3,800 | $29K | 100% |
| Filing → |
| FUSN | SELL | 2022-04-13 | $432K | — | Filing → |
| FUSN | SELL | 2022-04-08 | $16K | — | Filing → |
| FUSN | SELL | 2022-04-01 | $2K | — | Filing → |